- Abstract: Recently, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “shengnuo biopharmaceutical”) has submitted an application for change of guidance and filing.
- The listing board has been adjusted for the third time
- Several polypeptide APIs have passed official GMP certification in many countries
- It is worth mentioning that its wholly-owned subsidiaries, including Chengdu shengnuo biopharmaceutical Co., Ltd., have also realized commercial production.
Abstract: Recently, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “shengnuo biopharmaceutical”) has submitted an application for change of guidance and filing.
It intends to change the listing board from the gem to the sci tech innovation board, and the tutor is Minsheng securities. This is the third time that sinobio has adjusted its listing board. It’s worth noting that San Nuo
Recently, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “shengnuo biopharmaceutical”) has submitted an application for change of guidance and filing. It intends to change the listing board from the gem to the sci tech innovation board, and the tutoring institution is Minsheng securities. This is the third time that shengnuo biopharmaceutical has adjusted its listing board.
It is worth noting that Lepu Medical Co., Ltd., which invested 5.4 million yuan and held 9% shares, was also included in the list of shareholders of shengnuo biopharmaceutical.
The listing board has been adjusted for the third time
It is understood that shengnuo biopharmaceutical was founded in 2001, mainly engaged in research, development and sales of biomedical intermediates. It is a first-class international enterprise specializing in large-scale production of peptide and amino acid drugs, with total assets of 250 million.
At present, it has more than 50 key technologies for large-scale production of peptides that have been listed at home and abroad. The zero defect has passed the FDA certification of the United States.
It has undertaken the key research projects of National Eleventh Five Year Plan major new drug creation, and has successively won the titles of “National high-tech enterprise”, “Sichuan enterprise technology center” and “Chengdu polypeptide drug engineering technology research center”.
According to the data, shengnuo biopharmaceutical started the counseling and filing in September 2018, and began to prepare the listing change board in May 2019. The original application was intended to be listed on the SME board or gem to be changed to the science and technology innovation board. At the same time, it obtained the equity investment of Dachen venture capital in the same month.
However, it applied to change the listing board back to the gem in May 2019, calling it a change according to the needs of the company’s development. This is the third time that shengnuo biopharmaceutical has adjusted the listing board.
Several polypeptide APIs have passed official GMP certification in many countries
China’s polypeptide drug industry is still in its infancy and growth stage, but innovative drugs have caught up with the “east wind” of deepening the reform of drug evaluation and approval system in China. Products with definite clinical efficacy that are not listed at home and abroad will be put on the market quickly.
shengnuo biopharmaceutical mainly develops and produces raw materials and peptide drug preparations, which are used in autoimmune diseases and HIV-1 infected patients.
In addition, shengnuo biopharmaceutical also provides professional peptide drug research and development services, undertakes cro / C (d) Mo business of polypeptide projects at home and abroad, especially innovative polypeptide projects. It can produce 1.5 tons of polypeptide raw materials, 400 million tablets (granules) of solid preparations, 36 million bottles of freeze-dried powder injection and small volume injection, 5 million pieces of pre filled injection and 5 million pieces of cartridge injection.
At present, shengnuo biopharmaceutical has successfully realized the industrial transformation of a number of class I peptide new drugs for Chengdu Dior, Zhejiang Haizheng, Harbin Pharmaceutical Group, Hainan Zhonghe and frontier Biology (Nanjing).
It is worth mentioning that its wholly-owned subsidiaries, including Chengdu shengnuo biopharmaceutical Co., Ltd., have also realized commercial production.
Several polypeptide API production workshops have successively passed the official GMP certification of China, the United States, South Korea and Mexico.
Secondly, the raw material drug of carbetoxine and carbetoxine injection, which are the first domestic imitations and have independent intellectual property rights, have been approved and put on the market in 2016. Three of the products under research have submitted application for listing, including the generic drug of liraglutide injection.
Liraglutide injection is the only GLP-1 analogue in the current medical insurance catalogue. In 2018, the global sales volume was 4.468 billion US dollars, ranking the first in the overseas sales of diabetes drugs; the sales volume in China’s public medical institutions was nearly 500 million yuan, with a year-on-year increase of nearly 50%.
If the application of Sinochem for IPO of sci tech innovation board is successful, it is not difficult to imagine that it will have a huge market share.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.